Companies › Compugen
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| COM701 Experimental antibody | – | Phase 1 | Ovarian Cancer | Mar 2027 |
| COM503 | – | Phase 1 | Neoplasm | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06888921 | COM701 | Phase 1 | Ovarian Cancer | Oncology | Mar 2027 |
| NCT06759649 | COM503 | Phase 1 | Neoplasm | Oncology | Nov 2027 |
Cash and short-term investments of $100m on 2025-12-31; operating cash flow positive
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.